Charles G. Drake
Expertise in
6
conditions

Dr. Charles G. Drake

Internal Medicine
CUIMC/Herbert Irving Pavilion
161 Fort Washington Ave, 
New York, NY 
Offers Telehealth
Expertise in
6
conditions
CUIMC/Herbert Irving Pavilion
161 Fort Washington Ave, 
New York, NY 

Overview

Charles Drake is a primary care provider, practicing in Internal Medicine in New York, New York.

Dr. Drake is highly rated in 6 conditions, according to our data. His clinical expertise encompasses Renal Cell Carcinoma (RCC), Insomnia, Muscle Invasive Bladder Cancer, Nephrectomy, and Prostatectomy.

He is actively involved in clinical research, co-authoring 245 peer reviewed articles and participating in 7 clinical trials.

Specialties

Internal Medicine

Licenses

Internal Medicine in MD

Hospital Affiliations

New York-Presbyterian Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

CUIMC/Herbert Irving Pavilion
161 Fort Washington Ave, New York, NY 10032

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase I Trial of Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
A Phase I Trial of Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Enrollment Status: Completed
Publish Date: April 20, 2026
Intervention Type: Drug
Study Drugs: Apalutamide, Abiraterone, Docetaxel, Prednisone
Study Phase: Phase 1
A Pilot Study of Neoadjuvant Combination Spartalizumab and Canakinumab Prior to Radical Nephrectomy in Patients With Localized Clear Cell Renal Cell Carcinoma (SPARC-1 Trial)
A Pilot Study of Neoadjuvant Combination Spartalizumab and Canakinumab Prior to Radical Nephrectomy in Patients With Localized Clear Cell Renal Cell Carcinoma (SPARC-1 Trial)
Enrollment Status: Completed
Publish Date: April 15, 2026
Intervention Type: Drug
Study Drugs: Spartalizumab, Canakinumab
Study Phase: Early Phase 1
Phase II Randomized Placebo-Controlled Double-Blind Study of Salvage Radiation Therapy (SRT) Plus Placebo Versus SRT Plus Enzalutamide in Men With High-Risk PSA-Recurrent Prostate Cancer After Radical Prostatectomy
Phase II Randomized Placebo-Controlled Double-Blind Study of Salvage Radiation Therapy (SRT) Plus Placebo Versus SRT Plus Enzalutamide in Men With High-Risk PSA-Recurrent Prostate Cancer After Radical Prostatectomy
Enrollment Status: Completed
Publish Date: October 28, 2025
Intervention Type: Drug, Radiation
Study Drug: Enzalutamide
Study Phase: Phase 2
A Pilot Study of Neoadjuvant Non-fucosylated Anti-CTLA-4 (BMS-986218) + Degarelix Acetate vs. Degarelix Acetate Alone in Men With High-risk Localized Prostate Cancer
A Pilot Study of Neoadjuvant Non-fucosylated Anti-CTLA-4 (BMS-986218) + Degarelix Acetate vs. Degarelix Acetate Alone in Men With High-risk Localized Prostate Cancer
Enrollment Status: Completed
Publish Date: August 07, 2025
Intervention Type: Drug
Study Drugs: BMS-986218, Degarelix Acetate
Study Phase: Early Phase 1
Phase II Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma. HCRN: GU16-260
Phase II Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma. HCRN: GU16-260
Enrollment Status: Completed
Publish Date: July 10, 2025
Intervention Type: Drug
Study Drugs: Nivolumab, Ipilimumab
Study Phase: Phase 2
Randomized Phase 1b/2 Study of Nivolumab or Nivolumab Plus BMS-986253 in Combination With Intermittent Androgen Deprivation Therapy in Men With Hormone-Sensitive Prostate Cancer
Randomized Phase 1b/2 Study of Nivolumab or Nivolumab Plus BMS-986253 in Combination With Intermittent Androgen Deprivation Therapy in Men With Hormone-Sensitive Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 29, 2025
Intervention Type: Drug
Study Drugs: Nivolumab, Degarelix, BMS-986253
Study Phase: Phase 1/Phase 2
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients With Selected Solid Tumors
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients With Selected Solid Tumors
Enrollment Status: Completed
Publish Date: April 19, 2022
Intervention Type: Drug, Biological
Study Drugs: GEN-009 Adjuvant Vaccine, Nivolumab, Pembrolizumab
Study Phase: Phase 1/Phase 2
View 6 Less Clinical Trials

245 Total Publications

Corrigendum to "B7-H3 as a Therapeutic Target in Advanced Prostate Cancer" [European Urology 83 (2023) 224-238.
Corrigendum to "B7-H3 as a Therapeutic Target in Advanced Prostate Cancer" [European Urology 83 (2023) 224-238.
Journal: European urology
Published: August 07, 2026
Similar Doctors
Expertise in
39
conditions
Dr. Mark G. Lebwohl
Internal Medicine
Expertise in
39
conditions
Dr. Mark G. Lebwohl
Internal Medicine
Before you request

Icahn School Of Medicine At Mount Sinai

5 E 98th St, 
New York, NY 
 (3.6 miles away)
212-241-9728
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Mark Lebwohl is a primary care provider, practicing in Internal Medicine in New York, New York. Dr. Lebwohl is highly rated in 39 conditions, according to our data. His clinical expertise encompasses Plaque Psoriasis, Psoriasis, Pustular Psoriasis, and Generalized Pustular Psoriasis (GPP). Dr. Lebwohl is currently accepting new patients.

Expertise in
14
conditions
Dr. John P. Bilezikian
Internal Medicine
Expertise in
14
conditions
Dr. John P. Bilezikian
Internal Medicine
Before you request

NewYork Presbyterian Columbia University Irving Medical Center

180 Fort Washington Ave, 
New York, NY 
 (0.1 miles away)
212-305-2663
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

John Bilezikian is a primary care provider, practicing in Internal Medicine in New York, New York. Dr. Bilezikian is highly rated in 14 conditions, according to our data. His clinical expertise encompasses Hypoparathyroidism, Hypercalcemia, Milk-Alkali Syndrome, Parathyroidectomy, and Hormone Replacement Therapy (HRT). Dr. Bilezikian is currently accepting new patients.

Expertise in
13
conditions
Dr. Ryan C. Ungaro
Internal Medicine
Expertise in
13
conditions
Dr. Ryan C. Ungaro
Internal Medicine

MSSM-Optical Shop

17 E 102nd St, 
New York, NY 
 (3.4 miles away)
212-241-8100
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ryan Ungaro is a primary care provider, practicing in Internal Medicine in New York, New York. Dr. Ungaro is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Crohn's Disease, Viral Gastroenteritis, Ulcerative Colitis, Colonoscopy, and Endoscopy.

Frequently Asked Questions about Dr. Charles G. Drake

How do I make an appointment with Dr. Charles G. Drake?

You can book an appointment with Dr. Charles G. Drake by calling their office at 347-508-4296. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Charles G. Drake a top-rated expert for Renal Cell Carcinoma (RCC)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Charles G. Drake is classified as an Distinguished expert for Renal Cell Carcinoma (RCC), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Charles G. Drake specialize in?

While Dr. Charles G. Drake is a Internal Medicine, they have specific expertise in Renal Cell Carcinoma (RCC), Insomnia, and Muscle Invasive Bladder Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Internal Medicine.

Does Dr. Charles G. Drake participate in research or clinical trials?

Yes. Dr. Charles G. Drake has published 245 articles and abstracts on conditions like Renal Cell Carcinoma (RCC). You can view a list of Dr. Charles G. Drake's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Charles G. Drake accept my insurance?

Dr. Charles G. Drake accepts most major insurance plans, including Aetna and Cigna. We recommend calling the office directly at 347-508-4296 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Drake's expertise for a condition
ConditionClose
    View All 18 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile